

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUPPLEMENTAL ANNOUNCEMENT

SUPPLEMENTAL INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

INTRODUCTION

Reference is made to the annual report of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2025 (the “**Annual Report**”). Capitalised terms used in this announcement shall have the same meanings as those defined in the Annual Report unless the context otherwise requires.

This announcement is made by the board (the “**Board**”) of directors of the Company to provide supplemental disclosure of information relating to the significant investments of the Group in the Annual Report in accordance with paragraphs 32(4) and 32(4A) of Appendix D2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the recommended disclosure practices set out in the Stock Exchange’s Guide on Preparation of Annual Reports.

I. SIGNIFICANT INVESTMENTS

1. Investment details

As at 31 December 2025, the carrying amount of the Group’s financial assets at fair value through profit or loss was approximately RMB331 million, representing approximately 95.4% of the total assets of the Group as at that date. Such financial asset represents the Group’s equity investment in Beijing Kangchen Biological Technology Co., Ltd. (北京康辰生物科技有限公司) (“**Beijing Kangchen**”). Details of such investment are as follows:

- (a) name of the investee company: Beijing Kangchen Biological Technology Co., Ltd.;

- (b) principal activities: Beijing Kangchen is a limited liability company established in the PRC and is principally engaged in, among others, pharmaceutical technology development, technology consultancy, technology promotion, technology services, corporate management and supply chain management;
- (c) number of shares held and shareholding percentage: the Group holds 25.3 million shares in Beijing Kangchen, representing an equity interest of approximately 25.3%;
- (d) investment cost: approximately RMB224 million; and
- (e) investment funds: the Group's investment funds for Beijing Kangchen all come from the transfer proceeds of disposing of all the issued shares of NT Pharma International Limited ("**NT International**") on April 21, 2020. NT Pharma Pacific Company Ltd ("**NT Pacific**"), an indirectly wholly – owned subsidiary of the Company, completed the subscription using part of the proceeds from the aforementioned share transfer.

The carrying amount of such investment as at 31 December 2025 was approximately RMB331 million, representing approximately 95.4% of the total assets of the Group of approximately RMB348 million as at that date.

2. Investment strategy

The Company has shifted the focus of its core business to the development of its high-technology business comprising a closed-loop ecosystem platform for “testing, treatment and rehabilitation management”, and the equity investment in Beijing Kangchen forms part of the Group's historical industrial layout.

In view of the Company's practical need at the current stage to optimise the allocation of its liquidity resources and to concentrate resources on the development of its core business, the Board has included the timely disposal of such equity investment within the scope of the Group's strategic considerations.

II. INVESTMENT PORTFOLIO, INVESTMENT POLICY AND RISK MANAGEMENT

1. Investment policy and objectives

The Group adheres to the following principles in its external investments:

- (a) liquidity management principle: the working capital requirements of the Company are fully taken into account when investment decisions are made, so as to ensure that external investments will not affect the normal operations and solvency of the Company;
- (b) risk controllability principle: the amount of any single investment, the investment concentration and the investment tenor must be commensurate with the financial strength and risk tolerance of the Company, and investments in highly leveraged and highly volatile financial products are strictly controlled; and
- (c) stable return principle: the objective is to obtain long-term and stable investment returns and strategic synergy value, rather than primarily pursuing short-term trading gains.

The Group's current investment portfolio principally comprises the equity investment in Beijing Kangchen, which accounts for a relatively high proportion primarily due to the accumulation of historical investments. The management will continue to assess the concentration risk of the investment portfolio and will adopt optimisation measures in a timely manner.

2. Risk management and control measures

In respect of unlisted equity investments, the Company has established and implemented the following risk management mechanisms:

- (a) the management conducts regular assessments of indicators of impairment in respect of such investment;
- (b) an independent valuer with relevant qualifications is engaged at the end of each year to carry out a fair value assessment in accordance with the International Valuation Standards; and
- (c) a dedicated valuation will be initiated immediately upon the occurrence of any triggering event, such as material deterioration in the operations of the investee, material adverse changes in industry policies, or the involvement of litigation.

Through the above mechanisms and tools, including fair value assessment and monitoring, shareholders' equity monitoring and legal risk monitoring, the Company manages the risks associated with its external investments.

3. Approval and oversight mechanisms

- (a) the Board is the highest decision-making body for the Group's external investment risk management, and is responsible for reviewing and approving major external investment proposals, regularly reviewing investment portfolio reports and risk exposure reports, and making decisions on investment strategies and exit plans; and
- (b) within the scope of authority delegated by the Board, the management is responsible for daily investment operations and risk monitoring, and reports regularly to the Board and the audit committee on the performance of the investment portfolio and the risk profile.

III. OTHERS

The supplemental information contained in this announcement is supplemental to the Annual Report and should be read in conjunction with the Annual Report. Save as disclosed in this announcement, all other information contained in the Annual Report remains unchanged.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 23 October 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.